SMA Newsroom

Read full text here

<p>Roche shared updates on the final results of the now-concluded SUNFISH study, which assessed the efficacy and safety of risdiplam in people living with SMA aged 2-25 years.</p>

Community update from Roche: Final five-year data from the pivotal SUNFISH (NCT02908685) study 

<p>Novartis shared updates on the results from Phase III STEER and Phase IIIb STRENGTH studies, evaluating intrathecal onasemnogene abeparvovec (OAV101 IT) in people living with SMA aged two to &lt;18 years.&nbsp;</p>

Community update from Novartis: Phase III STEER and Phase IIIb STRENGTH studies

Call for Research Lay Summary of the Projects

Call for Research website

Our Call for Research Projects

<h2><strong>We are proud to announce the five scientific projects that have been selected for funding through our Call for Research no. 12.</strong></h2>
<p><strong> </strong></p>
<h2>&nbsp;</h2>

Call for Research no. 12. Learn about the shortlisted projects!

For further details

<p>Biohaven released the results from their RESILIENT SMA clinical trial, and they did not meet the primary endpoint. Biohaven is currently analysing the data further and is engaging in discussion with Health Authorities.&nbsp;</p>

SMA Newsroom

Community update from Roche: Final five-year data from the pivotal SUNFISH (NCT02908685) study

Community update from Novartis: Phase III STEER and Phase IIIb STRENGTH studies

Call for Research no. 12. Learn about the shortlisted projects!

We are proud to announce the five scientific projects that have been selected for funding through our Call for Research no. 12.

Community Update Biohaven: RESILIENT Letter to SMA Community

Categories